Traditional government and
pharmaceutical-sponsored clinical trials have failed to identify a drug or
drug combination that works best for all patients with the same type of cancer
(click here for more information). In fact, what the trials have shown is that all available drugs work for some
patients and not for others, proving that there really is no such thing as the
best drug for the "average" cancer patient.
It is no surprise then that cancer
patients often respond to third line agents after having endured non-beneficial, trial
and error treatment with first and second line regimens.
Meanwhile, patients needlessly experience harmful side effects from
ineffective chemotherapy drugs administered to them at random. In addition, valuable treatment time is
wasted and clinically acquired multi-drug resistance can develop.
In the CytoRx™ Profile, 20 to 30 standard chemotherapy drugs and drug
combinations are tested in three separate cell death-based assay systems against
a patient’s living tumor cells to identify the most promising treatments for
that patient alone.
Studies have shown that drugs that were
active in Functional Tumor Cell Profiling tests were 7 times more likely to
benefit patients who received them than drugs that were inactive in profiling
tests. A
separate, written interpretation of test results by Larry Weisenthal, M.D.,
Ph.D.
